Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Input: Consider Input: Paragraph: The Agency for Health Care Administration banned Floridian Gardens Assisted Living Facility from taking new patients Friday, citing “an immediate serious danger to the public health, safety or welfare” at the Miami facility. The Miami Herald reports a survey uncovered at least two deaths and multiple falls due to “deficient practices.” The facility is owned by the same people that operated the Rehabilitation Center at Hollywood Hills. Regulators tried to shut down Floridian Gardens after the Hollywood deaths. A criminal investigation is ongoing into the deaths at the Hollywood facility. A telephone message could not be left Saturday and an email to the facility was not immediately returned. ___ Information from: The Miami Herald, http://www.herald.com Claim: Admissions ban on Florida nursing home tied to Irma deaths.

Output: Florida health officials will not allow new patients to be admitted to an assisted living facility associated with a nursing home where a dozen residents died after the facility lost power in a hurricane.


Input: Consider Input: Paragraph: Now the ranking Democrat on the Senate Commerce, Science and Transportation Committee is questioning the role played by nominee Nancy Beck in the decision to shelve the guidelines. Beck is not a medical doctor and has no background in virology. President Donald Trump has nominated Beck to be chairwoman and commissioner of the U.S. Consumer Product Safety Commission, a position that requires Senate confirmation. Beck is scheduled to appear before the Senate committee later this month. Emails obtained by The Associated Press show that Beck was the U.S. Centers for Disease Control and Prevention’s main point of contact in the White House about the proposed recommendations. At issue was a 63-page guide created by the CDC that would give community leaders step-by-step instructions for reopening schools, day care centers, restaurants and other facilities. Beck is currently on detail for the White House with the Office of Management and Budget, where she is coordinating review of pandemic-related stimulus measures, and of the CDC guidance. She has a doctorate in environmental health and has worked as a toxicologist, specializing in the study of the health risks from chemical substances to the human body. “I am deeply concerned by the nominee’s involvement in advocating for the deregulation of toxic chemicals known as PFAS and I also have questions about her potential involvement with the CDC coronavirus guidance,” said Sen. Maria Cantwell, the top Democrat on the committee, in a statement to AP. Cantwell sent a letter of inquiry on Wednesday to Beck, asking for more information. Beck did not immediately respond to questions from AP sent to her via email. Beck’s role in the coronavirus guidance document was revealed in a series of emails from late April obtained by the AP. On April 10, CDC Director Robert Redfield emailed the guidance to a group that included some of the president’s closest White House advisers, including Trump son-in-law Jared Kushner, and counselor Kellyanne Conway, and Dr. Anthony Fauci, the government’s top infectious disease expert. Redfield wrote that he wanted White House review and clearance to post the documents on the CDC website. By the time the administration had released its “Opening Up America Again” plan on April 17, the process had stalled. The emails show that the CDC’s chief of staff, Robert “Kyle” McGowan, emailed Beck on April 26 seeking an update. “We need them as soon as possible so that we can get them posted,” McGowan wrote. Beck responded that they still needed approval. “WH principals are in touch with the task force so the task force should be aware of status.” The next day McGowan checked with Beck again. “I have no word on revisions yet for the rest of the package. My understanding is it is still being reviewed,” she responded. One of Beck’s colleagues, Satya P. Thallam, followed up saying the White House Principal’s Committee had not yet responded. “However, I am passing along their message: they have given strict and explicit direction that these documents are not yet cleared and cannot go out as of right now — this includes related press statements or other communications that may preview content or timing of guidances.” McGowan responded that White House changes would cause further delay. “The comments and edits we get back will have to be reviewed at the CDC for scientific accuracy,” McGowan responded to Thallam and Beck. “We will not be able to post the document we get back from the WH quickly if there are a substantial number of edits.” On April 30, one day before Trump’s May 1 reopening goal, McGowan was told guidelines will “never see the light of day,” according to three sources inside CDC who were not authorized to publicly discuss the matter and spoke on condition of anonymity. In her letter, Cantwell said the emails raise “serious questions about whether you believe in preserving and respecting the scientific and professional integrity of scientists and health professionals that work at agencies like the CDC and the CPSC.” On Thursday, another committee Democrat cited AP’s story in calling on the administration to withdraw Beck’s nomination. “Nancy Beck reportedly led efforts to thwart CDC’s science-based guidance for protecting public health — exactly the wrong credential for a nominee to lead the CPSC, and clear reason her nomination should be withdrawn,” said Sen. Richard Blumenthal, D-Conn.  An OMB spokesperson said the initial submission to the office was the “start of the deliberative process, not the end, and everyone knows that,” and added the White House appreciated that Beck continued “serving her country by helping the government respond to this pandemic while her nomination was pending.” Before joining the Trump administration, Beck was a senior director for policy at the American Chemistry Council, the primary lobbying arm for U.S. chemical manufacturers. In that role, she frequently testified on Capitol Hill against stricter safeguards to protect human health and the environment from toxins. In 2017, she joined the Environmental Protection Agency as a top official in the Office of Chemical Safety and Pollution Prevention. She oversaw efforts to block or weaken Obama-era regulations on harmful substances including asbestos, and at the White House was involved in a rewrite of limits on PFAS. Those are class of chemicals used in making nonstick cooking pans and raincoats, and the chemicals have been linked to birth defects. Democrats and environmentalists have opposed her nomination to lead the consumer agency. While she awaits Senate confirmation, Beck has been assigned to the White House Council of Economic Advisers, which consults with the president on matters of economic policy. On May 7, the day AP ran a story about the administration shelving the guidance, McGowan emailed Beck and copied Redfield. “When can we expect OMB comments on the rest of the guidance? We would really like to get these moving,” he wrote. Late that afternoon, the White House called the CDC and told the agency to resend a series of detailed “decision trees” that had been shelved. Emails showed staff working on the guidance said they would “stand down.” At a Senate hearing Tuesday on the coronavirus, Sen. Chris Murphy, D-Conn., asked Redfield about the status of that guidance. Redfield replied: “Soon.” ___ Dearen reported from Gainesville, Florida. Associated Press writer Zeke Miller contributed to this report. ___ Follow AP investigative reporters Jason Dearen at http://twitter.com/JHDearen and Michael Biesecker at http://twitter.com/mbieseck Claim: Emails: Trump nominee involved in shelving CDC virus guide.

Output: A former chemical industry executive nominated to be the nation’s top consumer safety watchdog was involved in sidelining detailed guidelines to help communities reopen during the coronavirus pandemic, internal government emails show.


Input: Consider Input: Paragraph: Note: As of 2016, Hyland’s has stopped distributing their teething products in the United States. In October 2010, the Food and Drug Administration (FDA) notified consumers that Hyland’s Teething Tablets, a homeopathic product, intended to provide temporary relief of teething symptoms in children, was being recalled after that agency received “reports of serious adverse events in children.” The FDA stated the tablets contained “inconsistent amounts of belladonna” that could pose a serious risk of harm to children (potentially including seizures) and warned consumers to stop using and discard the product: The tablets are manufactured to contain a small amount of belladonna, a substance that can cause serious harm at larger doses. For such a product, it is important that the amount of belladonna be carefully controlled. FDA laboratory analysis has found that Hyland’s Teething Tablets contain inconsistent amounts of belladonna. FDA has received reports of serious adverse events in children taking this product that are consistent with belladonna toxicity. The FDA has also received reports of children who consumed more tablets than recommended, because the containers do not have child resistant caps. The FDA has not evaluated Hyland’s Teething Tablets for safety or efficacy, and is not aware of any proven clinical benefit offered by the product. FDA recommends that consumers not use this product and dispose of any in their possession. FDA advises consumers to consult their health care professional if their child experiences symptoms such as seizures, difficulty breathing, lethargy, excessive sleepiness, muscle weakness, skin flushing, constipation, difficulty urinating, or agitation after using Hyland’s Teething Tablets. Nine months later, in July 2011, Hyland’s announced the imminent return to market of their teething tablets product, stating they had modified the manufacturing process to ensure uniformity in dosage and had added child-resistant caps to the packaging: Hyland’s voluntarily took Teething Tablets off the market in October 2010. We chose to exercise an abundance of caution by making this decision. Hyland’s and the FDA conducted a thorough review of all of our manufacturing processes and reports. Together, we identified manufacturing processes of Teething Tablets that could be improved to ensure uniformity in dosage. We also used this opportunity to refine the production, packaging and testing protocols on this product. We’ve added a child-resistant cap and updated the packaging and are introducing new strengths of the same ingredients that have calmed teething babies and their moms for more than 85 years. We have made significant changes in our manufacturing process and introduced rigorous testing protocols. We have kept all of the same ingredients that have made Hyland’s Baby Teething Tablets effective and safe and improved effectiveness by increasing the homeopathic potency of each active ingredient. As homeopathic potency increases, raw drug concentration decreases, providing an even wider margin of safety than before. Following an FDA warning issued in September 2016 stating that “homeopathic teething tablets and gels may pose a risk to infants and children,” Hyland’s announced they would discontinue manufacture of the product (although some may remain on store shelves or available for purchase online): For generations, we at Hyland’s have been proud to offer safe, effective and natural health solutions to families like yours. In fact, for over 90 years, parents have trusted Hyland’s teething medicines to ease the pain of teething in infants. We thank you for that longstanding trust. It is therefore with much sadness that we share with you that we have chosen to discontinue the distribution of our Hyland’s teething medicines in the United States. This decision was made in light of the recent warning issued by the Food & Drug Administration (FDA) against the use of homeopathic teething tablets and gels. This warning has created confusion among parents and limited access to the medicines. A February 2017 report suggested that hundreds of cases in which children had been taken ill (or even died) after the use of Hyland’s homeopathic teething products had been relayed to the FDA over the years: Babies who were given Hyland’s teething products turned blue and died. Babies had repeated seizures. Babies became delirious. Babies were airlifted to the hospital, where emergency room staff tried to figure out what had caused their legs and arms to start twitching. Claim: "Hyland's Teething Tablets have been discontinued for causing ""adverse events"" in children."


Output: Over a 10-year period, from 2006 to 2016, the FDA collected reports of “adverse events” in more than 370 children who had used Hyland’s homeopathic teething tablets or gel, a similar product that is applied directly to a baby’s gums. Agency records show eight cases in which babies were reported to have died after taking Hyland’s products, though the FDA says the question of whether those products caused the deaths is still under review.